Virax Biolabs has entered into an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to markets accepting the CE mark, namely the EU. The test kit is for the detection and differentiation of ribonucleic acid from AIV and the H5, H7 and H9 subtypes, including the H5N1 strain currently spreading in Europe. The test kit is for use in laboratory settings and can help healthcare professionals accurately identify an AIV infection.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRAX: